CD8A and neoplasm: In order to restore the proliferation, migration, and anti-tumor activity of CD8+T cells, it is advantageous to repress the PD-1/PD-L1 signal pathway using drugs such as nivolumab, durvalumab, atezolizumab, avelumab, and pembrolizumab.